Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Denton

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Arthritis and Rheumatism|December 14, 2004
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistJ H Korn, M Mayes, M Matucci Cerinic, et al.
Arthritis Research & Therapy|January 26, 2019
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) surveyJ Blagojevic, S Bellando-Randone, G Abignano, et al.
Clinical Rheumatology|May 22, 2019
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher studyJelena Blagojevic, G Abignano, J Avouac, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2024
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, M Geroldinger-Simić, A Kreuter, et al.
Arthritis and Rheumatism|September 10, 2011
A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediatorsJ C A Broen, L Bossini-Castillo, L van Bon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2017
European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosisR Knobler, P Moinzadeh, N Hunzelmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 10, 2017
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, P Moinzadeh, N Hunzelmann, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Arthritis and Rheumatism|December 14, 2004
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistJ H Korn, M Mayes, M Matucci Cerinic, et al.
Arthritis Research & Therapy|January 26, 2019
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) surveyJ Blagojevic, S Bellando-Randone, G Abignano, et al.
Clinical Rheumatology|May 22, 2019
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher studyJelena Blagojevic, G Abignano, J Avouac, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2024
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, M Geroldinger-Simić, A Kreuter, et al.
Arthritis and Rheumatism|September 10, 2011
A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediatorsJ C A Broen, L Bossini-Castillo, L van Bon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2017
European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosisR Knobler, P Moinzadeh, N Hunzelmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 10, 2017
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, P Moinzadeh, N Hunzelmann, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Pageof 10